P173 Plasma and tumour tissue TP53-gene expression in patients with high grade serous advanced ovarian cancer

2019 ◽  
Author(s):  
J Martinez-Garcia ◽  
P Sanchez Henarejos ◽  
MD Jimenez Lucas ◽  
A Puertes Boix ◽  
A Anton Garcia ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Tp53 Gene ◽  
Tumour Tissue ◽  
High Grade

scholarly journals Prognostic gene expression signature for high-grade serous ovarian cancer

2020 ◽  
Vol 31 (9) ◽  
pp. 1240-1250 ◽  
Author(s):  
J. Millstein ◽  
T. Budden ◽  
E.L. Goode ◽  
M.S. Anglesio ◽  
A. Talhouk ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Gene Expression Signature ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Expression Signature ◽  
Prognostic Gene

scholarly journals The forkhead box L2 transcription factor (FOXL2) is differentially expressed in high-grade serous ovarian cancers.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Ovarian Tumors ◽  
High Grade ◽  
Normal Ovary ◽  
Primary Tumors ◽  
Forkhead Box ◽  
Ovarian Cancers

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (2, 3). We identified the forkhead box L2, (FOXL2) (4) as among the genes whose expression was most different in HGSC ovarian tumors. FOXL2 expression was significantly lower in ovarian tumors relative to normal ovary. FOXL2 has established roles in ovarian development (4, 5), and the FOXL2 gene is mutated in granulosa-cell tumors of the ovary (6). These data indicate FOXL2 might also be perturbed, at the level of gene expression, in high-grade serous ovarian cancers.

Poly (ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer

2021 ◽  
Author(s):  
Olivia Le Saux ◽  
Hélène Vanacker ◽  
Fatma Guermazi ◽  
Mélodie Carbonnaux ◽  
Clémence Roméo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Homologous Recombination ◽  
Advanced Ovarian Cancer ◽  
Cost Effective ◽  
Preclinical Study ◽  
The Body ◽  
Synergistic Activity ◽  
High Grade ◽  
First Line ◽  
Homologous Recombination Deficiency

Homologous recombination deficiency and VEGF expression are key pathways in high-grade ovarian cancer. Recently, three randomized practice changing trials were published: the PAOLA-1, PRIMA and VELIA trials. The use of PARP inhibitors (PARPi) following chemotherapy has become standard of care in first line. Combination of PARPi with anti-angiogenic agents has demonstrated synergistic activity in preclinical study. This review summarizes the body of evidence supporting the efficacy and safety of the combination of PARPi and anti-angiogenic drugs in first-line homologous recombination deficiency high-grade ovarian cancer leading to US FDA and EMA approvals. This double maintenance is supported by: a large benefit with bevacizumab + olaparib compared with olaparib alone, a rationale for additive effect, and a good safety and cost-effective profile.

scholarly journals Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures

2016 ◽  
Vol 141 (1) ◽  
pp. 95-100 ◽  
Author(s):  
Boris Winterhoff ◽  
Habib Hamidi ◽  
Chen Wang ◽  
Kimberly R. Kalli ◽  
Brooke L. Fridley ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Clear Cell ◽  
Molecular Classification ◽  
High Grade ◽  
Gene Expression Signatures

scholarly journals Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2

Oncogene ◽  
2004 ◽  
Vol 23 (49) ◽  
pp. 8171-8183 ◽  
Author(s):  
Loris De Cecco ◽  
Luigi Marchionni ◽  
Manuela Gariboldi ◽  
James F Reid ◽  
M Stefania Lagonigro ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Expression Profiling ◽  
Advanced Ovarian Cancer ◽  
Molecular Signature ◽  
Fibroblast Growth Factor 2 ◽  
Fibroblast Growth
Sign in / Sign up

Export Citation Format

Share Document